CART-ANT308
Pancreatic Cancer / Solid Tumors
Pre-clinicalActive
Key Facts
About Cambium Oncology
Cambium Oncology is pioneering a novel class of immunotherapies targeting the VIP/VPAC axis, an immunosuppressive pathway exploited by cancer cells. Its lead candidate, CAMV-01, is a VIP antagonist designed to re-activate cytotoxic T-cells, with a pipeline that includes small molecules, cell therapies, and long-acting constructs. Founded on IP from Emory University and led by a seasoned team, the company employs a biomarker-driven, combination-focused strategy to de-risk development in a high-value oncology market. Cambium is a private, pre-revenue company advancing its programs through preclinical and early clinical development.
View full company profileTherapeutic Areas
Other Pancreatic Cancer / Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| SereneRF for Soft Tissue Tumors | Thermedical | Early Clinical |
| Oncology Platform Discovery | Renovaro BioSciences | Pre-clinical |